Invokana, Farxiga, and Xigduo receive new warning label to include acute kidney injury
The FDA recently strengthened the warning label for SGLT2 inhibitors that include the active ingredient canagliflozin and dapagliflozin. The updated warning label includes mention of acute kidney injury and offers advice to health care professionals on methods to prevent or lower the risk of injury.
This comes nearly a year after a previous warning mentioned SGLT2 could be responsible for the development of a rare condition known as diabetic ketoacidosis.
Developing an acute kidney injury from SGLT2 inhibitors
Invokana, Farxiga, and Xigduo work by having the kidneys remove sugar from the body. Glucose or sugars are then deposited into the urine where it will then exit the body. If the kidneys were to become impaired or they became weak from exhaustion due to overuse, then the patient may experience an acute kidney injury.
The new warning also mentions that doctors should test the patient for kidney function before prescribing SGLT2 inhibitors, and health care professionals should also consider all the probable risk factors that may predispose the patient to an acute kidney injury.
List of complications to consider that may lead to an acute kidney injury from SGLT2 inhibitors
Below is a list probable risk factors to consider that the FDA has identified:
- Patients with decreased blood volume
- Patients diagnosed with chronic kidney insufficiency
- Patients diagnosed with congestive heart failure
- Patients who take ACE (angiotensin-converting enzyme inhibitor)
- Patients who take ARBs (angiotensin-receptor blockers)
- Patients who take NSAIDs (nonsteroidal anti-inflammatory drugs)
What the new warning for Invokana, Farxiga, and Xigduo means for patients
While the most recent FDA warning may help prevent future incidents of acute kidney injury due to SGLT2 inhibitors, this message may not have come soon enough for some patients. There have been several reports submitted to the FDA’s Medwatch programs where the patient experienced kidney failure and required emergency treatment along with dialysis.
The FDA believes there could be other undocumented cases where patients developed an acute kidney injury due to Invokana and did not know the two were related since the information was not available at the time of injury.
Invokana, Farxiga, Xigduo Lawsuits for Acute Kidney Injury and other Side Effects
The Abbott Law Group, P.A. is currently investigating injuries related to the use of Invokana, Farxiga, and Xigduo. If you or a loved one were diagnosed with diabetic ketoacidosis, a myocardial infarction, stroke, or a kidney injury, then you may be legally entitled to receive compensation through a SGLT2 inhibitor lawsuit.
Contact us today for a free case review to see if you may be eligible to join an Invokana lawsuit today.